CSRXP: WHITE HOUSE FRAMEWORK FAILS ON PROMISE TO LOWER DRUG PRICES
Framework Fails to Hold Big Pharma Accountable and Lower Drug Prices for the… Read More
Framework Fails to Hold Big Pharma Accountable and Lower Drug Prices for the… Read More
U.S. Food & Drug Administration Approval of Cyltezo Marks Second… Read More
Committee Mark Up Targets Brand Name Drug Companies’ Anti-Competitive… Read More
Americans Blame Big Pharma for Out-of-Control Drug Prices, Reject Bogus… Read More
Committee Leaders Put Forward Solutions to Lower Prescription Drug Prices for… Read More
Administration Proposal Would Increase Competition, Transparency and Value —… Read More
Speech Adds to Unprecedented Momentum for Action, Now Lawmakers Must Deliver… Read More
Lawmakers Must Build on Momentum For Action With Permanent Repeal of Rebate… Read More
Interchangeable Products Will Help Increase Prescription Drug Competition and… Read More
Unanimous, Bipartisan Passage of Bills Targeting Brand Name Drug Companies’… Read More
Campaign Looks Forward to Working with Administration and Congress to Crack… Read More
U.S. House Oversight & Reform Committee Report Shines Light on Branded… Read More